Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
Proposed changes to the UK statutory scheme for controlling the costs of branded medicines bought by the National Health Service would hit company profits and could deter biosimilar launches.
The European Commission continues to try and ease concerns EU member states have over its proposals to drive cooperation on health technology assessments and the mandatory use of joint clinical assessment reports.
A draft circular on pricing has raised the spectre of price controls being applied with little warning for companies, the Colombian research-based pharmaceutical industry has warned.
Industry says that if cross country-coalitions on pricing and reimbursement are to succeed, the member countries need to be similar in terms of GDP and to guarantee pricing is kept confidential.
Vertex has rejected the “final offer” put forward by the National Health Service in England for its cystic fibrosis drugs, including Orkambi. The company’s chief executive wants a meeting with the head of the NHS.
Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.